Amgen has participated in an $8.4m round for the antibody therapeutics developer, which aims to tackle chronic kidney disease.
DJS Antibodies, a UK-based developer of antibody therapeutics for inflammatory diseases, has received £6m ($8.4m) of funding from investors including Amgen Ventures, the corporate venturing arm of pharmaceutical firm Amgen.
Medical research charity LifeArc’s Seed Fund co-led the round with Sedgwick Yard, with participation from Oxford Sciences Innovation, a venture capital vehicle for University of Oxford, which was identified as an existing investor.
The investment will finance the development of two of DJS’s assets, including one being developed to treat…
